USP's Response: USP in a Global Era

Williams, Roger L.
September 2011
Pharmaceutical Technology;Sep2011, Vol. 35 Issue 9, p93
Trade Publication
In this article the author discusses the issue concerning the globalization of United States Pharmacopeia (USP). He notes that the organization's investments have been focused on the advancement of its laboratories in Maryland, India, China, and Brazil that are all supporting USP's standards-setting body. Moreover, the author mentions that USP is working with the U.S. Food and Drug Administration (FDA) to update the needed standards for public monographs.


Related Articles

  • Pharmacy Outlook '12: The U.S. Pharmacopeia (USP) Roger Williams, CEO. Williams, Roger // Chain Drug Review;1/2/2012, Vol. 34 Issue 1, p116 

    The article presents the views of Roger Williams, chief executive officer (CEO) of the U.S. Pharmacopeia (USP), on the 2012 outlook for pharmaceutical industry in the U.S. He is critical on the plans of the pharmaceutical industry and the Food and Drug Administration (FDA) in responding to the...

  • Elemental Impurity Requirements. Schoneker, David R. // Contract Pharma;Mar2013, Vol. 15 Issue 2, p43 

    A letter to the editor is presented in response to the article "Elemental Impurities Control - USP's New Standards to be required by May 2014" by Dr. Anthony DeStefano and Dr. Kahkashan Zaidi in the October 2012 issue.

  • Ensuring Drug Quality: A Complex Task in a Globalized Era. Williams, Roger L. // Pharmaceutical Executive;Jan2011, Vol. 31 Issue 1, p16 

    The article discusses the initiative of the U.S. Pharmacopeial Convention (USP) on ensuring quality drugs to pace with the global market modernization. It states that Food and Drug Administration (FDA) Commissioner Margareta Hamburg believes that one of the pressing tasks for FDA and USP is in...

  • A change is coming: Proposed USP <800>. PENNELL, SUSAN // Pharmacy Today;Apr2015, Vol. 21 Issue 4, p59 

    The article focuses on the changes to be proposed in legally recognized standards of drugs by the U.S. Pharmacopeial (USP) Convention. Topics discussed include enforcement of drug standards by the U.S. Food and Drug Administration (FDA), guidelines for safe handling of hazardous drugs, and...

  • Up Close and Personal. Drakulich, Angie // Pharmaceutical Technology;May2011, Vol. 35 Issue 5, p44 

    The article discusses the regulation of over-the-counter (OTC) drugs in the U.S. It highlights the OTC Monograph System by the Food and Drug Administration (FDA) which reviews the chemical compounds available to consumers in OTC form. It states that drug standards are published by the U.S....

  • 'Capability of the Art' versus 'Fit for Use'. Tan, Charles Y. // Pharmaceutical Technology Europe;May2011, Vol. 23 Issue 5, p56 

    The US Pharmacopeia draft chapter <1033> Biological Assay Validation has made significant progress toward fit for use as a guiding principle for assay validation. However, feedback from the FDA at the third USP Bioassay Workshop revealed concern at the lack of criteria for "intermediate...

  • USP Extends Time to Meet Residual Solvent Standards.  // BioPharm International;Aug2007, Vol. 20 Issue 8, p12 

    The article reports on the decision of the U.S. Pharmacopeia (USP) to extend the implementation period for its USP-National Formulary (USP-NF) from July 1, 2007 to July 1, 2008. The USP-NF requirements are designed to ensure consistency from one manufacturer to another in different areas...

  • Quick Saves and Near Misses.  // Pharmaceutical Technology;Mar2010, Vol. 34 Issue 3, p16 

    The article discusses the importance of an information technology quality-management system (QMS) in pharmaceutical manufacturing factories in the U.S. The author states that the U.S. Pharmacopeia (USP) has released a statement that their product failed to meet USP's dissolution requirements....

  • Regulators Grow Global Presence.  // Pharmaceutical Technology;Dec2009 Corporate Capabilities Supp, p83 

    The article focuses on the move of the U.S. Food and Drug Administration (FDA) in opening several new FDA offices overseas. It notes that India will be having the highest number of FDA staff in which a growing amount of regulated products are being imported into the U.S. It also notes that the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics